Status and phase
Conditions
Treatments
About
This is a Phase 3, open-label, international, multicenter study of bezuclastinib in combination with sunitinib. This is a multi-part study that will enroll approximately 482 participants. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of bezuclastinib to be used in subsequent parts in approximately 20 participants who have received at least one prior line of therapy for Gastrointestinal Stromal Tumors (GIST) and 2) evaluating the potential for drug-drug interactions between bezuclastinib and sunitinib in approximately 18 participants who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 participants who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of bezuclastinib plus sunitinib to sunitinib alone with participants being randomized in a 1:1 manner. This study also contains two substudies: 1) a drug-drug interactions (DDI) substudy will investigate the potential for bezuclastinib to be a Cytochrome P450 (CYP)3A4 inducer in approximately 16 participants who have received at least one prior line of therapy for GIST and 2) a substudy intended to test the efficacy of bezuclastinib and sunitinib as first-line (1L) treatment of GIST in approximately 40 participants with KIT exon 9 mutations and no prior systemic therapy (with the exception of up to 10 participants with ongoing imatinib therapy of ≤4 weeks).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Histologically confirmed locally advanced, metastatic, and/or unresectable GIST. Molecular pathology report must be available for Part 2; if molecular pathology report is unavailable or inadequate, an archival or fresh tumor tissue sample will be required to evaluate mutational status prior to randomization. (GIST 1L Substudy: must have documented mutation in KIT Exon 9 with an available molecular pathology report; archival or fresh tumor tissue sample will be required)
Documented disease progression on or intolerance to imatinib (Part 1a, Part 1b, Part 2, DDI Substudy)
Participants must have received the following treatment:
Have at least 1 measurable lesion according to mRECIST v1.1 (Part1a, Part 1b, Part 2, GIST 1L Substudy)
Eastern Cooperative Oncology Group (ECOG) Status
Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits
Key Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
482 participants in 7 patient groups
Loading...
Central trial contact
Cogent Biosciences
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal